SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
MALVERN, Pa., Sept. 06, 2016 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that Dr. Neal Walker, President & Chief Executive Officer, will present at the Morgan Stanley 2016 Global Healthcare Conference on Wednesday, September 14, 2016 at 11:05 a.m. EDT at the Grand Hyatt, New York, NY.
A live audio webcast of the Aclaris presentation can be accessed by visiting the “Investors” section of the Company’s website at www.aclaristx.com. A replay of the webcast will be archived on the Aclaris Therapeutics website for 30 days following the presentation date.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting Aclaris’ website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Vice President / Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
